How do you know when it’s time to make your next big career move? With International Women’s Day around the corner, we are excited to feature Avni Patel Thompson, Founder and CEO of Milo. Avni is building technology that directly supports the often overlooked emotional and logistical labor that falls on parents—especially women. Milo is an AI assistant designed to help families manage that invisible load more efficiently. In this episode, Avni shares her journey from studying chemistry to holding leadership roles at global brands like Adidas and Starbucks, to launching her own ventures. She discusses how she approaches career transitions, the importance of unpleasant experiences, and why she’s focused on making everyday life easier for parents. [01:26] Avni's University Days and Early Career [04:36] Non-Linear Career Paths [05:16] Pursuing Steep Learning Curves [11:51] Entrepreneurship and Safety Nets [15:22] Lived Experiences and Milo [19:55] Avni’s In Her Ellement Moment [20:03] Reflections Links: Avni Patel Thompson on LinkedIn Suchi Srinivasan on LinkedIn Kamila Rakhimova on LinkedIn Ipsos report on the future of parenting About In Her Ellement: In Her Ellement highlights the women and allies leading the charge in digital, business, and technology innovation. Through engaging conversations, the podcast explores their journeys—celebrating successes and acknowledging the balance between work and family. Most importantly, it asks: when was the moment you realized you hadn’t just arrived—you were truly in your element? About The Hosts: Suchi Srinivasan is an expert in AI and digital transformation. Originally from India, her career includes roles at trailblazing organizations like Bell Labs and Microsoft. In 2011, she co-founded the Cleanweb Hackathon, a global initiative driving IT-powered climate solutions with over 10,000 members across 25+ countries. She also advises Women in Cloud, aiming to create $1B in economic opportunities for women entrepreneurs by 2030. Kamila Rakhimova is a fintech leader whose journey took her from Tajikistan to the U.S., where she built a career on her own terms. Leveraging her English proficiency and international relations expertise, she discovered the power of microfinance and moved to the U.S., eventually leading Amazon's Alexa Fund to support underrepresented founders. Subscribe to In Her Ellement on your podcast app of choice to hear meaningful conversations with women in digital, business, and technology.…
Player FM - Internet Radio Done Right
Checked 1d ago
Lisätty one vuosi sitten
Sisällön tarjoaa GRAIL. GRAIL tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
))
Daily Deals
The Cancer SIGNAL
Merkitse kaikki (ei-)toistetut ...
Manage series 3559285
Sisällön tarjoaa GRAIL. GRAIL tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
The Cancer SIGNAL brings together experts from the cancer community to discuss the latest innovations transforming cancer detection and shifting the cancer paradigm. The podcast is presented by GRAIL and hosted by Kim Thiboldeaux, former CEO and Executive Chair of the Cancer Support Community.
…
continue reading
28 jaksoa
Jaa
Merkitse kaikki (ei-)toistetut ...
Manage series 3559285
Sisällön tarjoaa GRAIL. GRAIL tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
The Cancer SIGNAL brings together experts from the cancer community to discuss the latest innovations transforming cancer detection and shifting the cancer paradigm. The podcast is presented by GRAIL and hosted by Kim Thiboldeaux, former CEO and Executive Chair of the Cancer Support Community.
…
continue reading
28 jaksoa
Kaikki jaksot
×
Dr. Patrick McGill was instrumental in introducing Community Health Network to multi-cancer early detection (MCED) testing and integrating it into routine screenings offered to patients. Dr. McGill is Executive Vice President and Chief Transformation Officer at Community Health Network, and as a practicing primary care physician he believes strongly in the importance of catching cancer as early as possible to improve outcomes for patients. In this episode he shares how MCED has made an impact at Community Health Network. Watch the full episode on YouTube: https://youtu.be/X9PyQeiO0HM Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/ The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. Rx only. See Important Safety Information: http://bit.ly/33m8pFa Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.…
How does cancer screening fit into one’s longevity goals? Dr. Ummat, a preventative medicine physician dedicated to changing the approach to aging, shares insights on the role of preventative care in maintaining long-term health, why proactive screening matters, and how new technologies like multi-cancer early detection testing can change the way we screen for cancer. Watch the full episode on YouTube: https://youtu.be/D0Hi4NLC-qo Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/ The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. See Important Safety Information: http://bit.ly/33m8pFa Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.…
Dr. Eric Klein, Distinguished Scientist at GRAIL, provides a research update from GRAIL’s 2024 findings on multi-cancer early detection (MCED) testing, presented at ASCO, ESMO, AACR and more. He explores insights from the first real-world evaluation of repeat multi-cancer early detection testing, data on how multi-cancer early detection (MCED) testing is helping cancer survivors by detecting recurrence and new cancers, and findings on using MCED to detect high grade, clinically significant prostate cancer over indolent cases. Plus, the economic and emotional impacts of cancer screening, and three insightful case studies. Watch the full episode on YouTube: https://youtu.be/QU6s3P1B5Bo Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/ The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. Rx only. See Important Safety Information: https://www.galleri.com/safety-information Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.…
At their doctor’s recommendation, Rich and Staci each took a multi-cancer early detection test during a routine checkup. Despite having no symptoms, Rich received a Cancer Signal Detected result, while Staci, who had a strong family history of cancer, did not. Listen to their story and learn about the impact of early cancer detection. Watch the full episode on YouTube: https://youtu.be/NKY3lX9PGYs View Rich and Staci’s story: https://youtu.be/z7M_ebq4Tj4?si=-C9cGsmx7MFzcKzc Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/ The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. See Important Safety Information: http://bit.ly/33m8pFa Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.…
T
The Cancer SIGNAL
Seven in 10 Americans are behind on at least one routine cancer screening. Jody Hoyos, CEO of the Prevent Cancer Foundation, joins Susanna to discuss the critical role of early cancer detection. She addresses the most common misconceptions about cancer screening and explains the importance of proactive screening, even when no symptoms are present. Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Introducing our new host, Susanna Quinn! Susanna is a cancer survivor, entrepreneur, writer and philanthropist. Diagnosed with stage three ovarian cancer in 2019, Susanna underwent aggressive treatment and achieved cancer-free status by September of the same year. In this episode, Kim Thiboldeaux, the Cancer SIGNAL’s inaugural host, interviews Susanna about her cancer story and passes the torch. Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
T
The Cancer SIGNAL
1 21 – Overcoming Medical Mistrust, Bias, and Access to Cancer Screening in the LGBTQ+ Community 25:29
Dr. Scout, Executive Director of the National LGBT Cancer Network, discusses how the LGBTQ+ community faces unique challenges in cancer screening. Dr. Scout highlights the increased cancer risks due to social factors, like discrimination and medical mistrust, and emphasizes the importance of inclusive healthcare provider training. The National LGBT Cancer Network works to educate both the community and providers, runs support groups for LGBTQ+ cancer survivors, and is developing a more comprehensive list of welcoming providers. Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Jon Rendina and Dwight Venson of Whitman-Walker, a healthcare center historically focused on the LGBTQ+ community, join us to delve into how LGBTQ+ people and people of color face disparities in cancer incidence. Whitman-Walker, Cancer Support Community, and GRAIL are collaborating on INCLUDE, a study to evaluate multi-cancer early detection (MCED) testing’s impact within federally qualified health centers. The goal: make this kind of cancer screening available to more people in the future. Jon and Dwight discuss barriers to access, how LGTBQ+ and minority experiences of cancer care can be different, and how MCED testing may play a role in helping underserved groups. Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Diverse clinical trials provide more meaningful data to researchers, but too many trials are based around monolithic audience groups. In early disease detection, particularly in conditions like cancer, diversity in clinical trials is especially important. Our guests, Eucharia Borden of the cancer nonprofit Family Reach and Dr. Gary Puckrein of the National Minority Quality Forum, discuss why diversity in clinical trials is critical and how to foster inclusivity in clinical research, getting us closer to healthcare equity. Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
After supporting her husband through his shocking cancer experience, Cindy decided to take a multi-cancer early detection test as recommended by her doctor. She was once again shocked when she received a “cancer signal detected” result, leading to a cancer diagnosis. Join us to hear about Cindy’s experience with early detection, treatment, and eventual remission, and what she learned along the way. We want your feedback! Please take our podcast survey: https://bit.ly/42R4wGi Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Join host Kim Thiboldeaux and Krissa Smith, VP of Mission Partnerships at Susan G. Komen, as they continue unraveling how the BRCA gene and other DNA mutations impact hereditary cancer risk. In this episode, Krissa shares personal stories about her family's experiences with genetic testing and how they’ve chosen to respond. Krissa also discusses cancer screening best practices and how multi-cancer early detection testing can play a role. Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Krissa Smith, Vice President of Mission Partnerships at Susan G. Komen, joins us to discuss the complexities of the BRCA gene and its impact on hereditary cancer risk. Krissa shares her family's experiences with genetic mutations, including the p53 gene, and explains the importance of genetic testing and how it can work in partnership with evolving cancer screening technology. Stay tuned for part 2 to learn more about genetics, cancer risk, and the importance of early detection. Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Meet Tami, manager of a Christmas tree farm in rural Oregon. Cancer has had a profound impact on Tami’s life, from her grandmother's diagnosis more than 30 years ago to her own 2017 diagnosis to her participation in the PATHFINDER study. Tami shares what she’s learned about cancer and the importance of proactive screening, including her own experiences with multi-cancer early detection (MCED) testing. Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
In the years since the COVID-19 pandemic began, cancer screening has changed, necessitating inventive strategies. Epidemiologists Dr. Alpa Patel (Senior Vice President of Population Science, American Cancer Society) and Dr. Tina Clarke (Vice President of Epidemiology and Distinguished Scientist, GRAIL) return to The Cancer SIGNAL to discuss how the pandemic changed access to cancer screening, the impact it had on diagnosing cancer, and where that leaves the screening landscape today. Please take our survey to share your thoughts on The Cancer SIGNAL: https://bit.ly/3sQkbrN Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
T
The Cancer SIGNAL
What did researchers learn when they studied a multi-cancer early detection test in a population of more than 6,000 patients? The PATHFINDER study, recently published in The Lancet, explored that question and produced useful insights. Dr. Chuck McDonnell, a radiologist with Sutter Medical Group and principal investigator for PATHFINDER, joins this episode to discuss how the study worked, highlights of the results, and what they could mean for the future of cancer screening. Transcripts available at https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/…
Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.
Daily Deals
Daily Deals
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
))
